Login to Your Account



Ariad completes rolling NDA for brigatinib

By Michael Fitzhugh
Staff Writer

Tuesday, August 30, 2016

Nearly six months after downsizing, in part to focus on gaining regulatory approvals for its ALK inhibitor brigatinib, Ariad Pharmaceuticals Inc. has completed a rolling submission of a new drug application for the candidate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription